PF-Atlas › Clinical Trials › NCT06219239

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

KL003 cell injection Drug Product · Not specified

Registry ID
NCT06219239
Phase
Not specified
Status
Recruiting
Drug / intervention
KL003 cell injection Drug Product
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Start
2024-01-04
Enrollment
3
Locations
1

About this trial

This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells transfusion in subjects with transfusion-dependent β-thalassemia.

View NCT06219239 on ClinicalTrials.gov →

Explore related

All KL003 cell injection Drug Product trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT06219239 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.